Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group
 study of ascending single IV doses of ILV-094, an investigational drug, administered to
 healthy subjects. In addition, there will be one sub-cutaneous dose cohort, which will follow
 the 25 mg IV dose.
-  Healthy subjects (Men or women of nonchildbearing potential ), aged 18 to 50 years.

 -  Body mass index in the range of 18 to 30 Kg/m2 and body weight greater than 50 Kg.

 -  Healthy as determined by the investigator on the basis of medical history, physical
 examination, clinical laboratory test results, vital signs, and 12-lead
 electrocardiogram.